Penn I-Corps Launches Spring 2023 cohort
The cohort started at the end of February and is underway. Teams are currently engaged in reaching out and conducting Customer discovery interviews.
Managing Director John Swartley Featured on The Philadelphia Business Journal Cover
This in-depth interview with Swartley provides a comprehensive history about technology transfer at Penn as well as the establishment and current success of PCI.
Penn Ranks First in Licensing Income in AUTM Annual Report
Penn officially ranked number one in terms of licensing income in the latest Association of University Technology Managers (AUTM) annual survey, which included 153 reporting institutions.
PCI Activities Highlighted by the CEO Council for Growth
The CEO Council for Growth recently highlighted PCI's annual review and JP Morgan Conference event in its newsletter.
PACT Enterprise Awards
PCI supported Penn spinouts Interius BioTherapeutics, Verismo Therapeutics, viTToria biotherapeutics, Exyn Technologies, and Avisi Technologies are all nominated for awards.
Mitchell Lab’s Targeted Prenatal Therapy for Mothers and Their Babies Addresses Gap in Health Equity
The researchers’ successful trials in mice show that the technology may potentially lead to promising treatment options for humans with pre-eclampsia.
Penn Medicine, CHOP receive $25M anonymous gift to accelerate research in rare genetic brain disorders
The donation will establish the Center for Epilepsy and Neurodevelopmental Disorders, which will initially focus on developing therapies for disorders related to genetic mutations that are linked to a
Equimeter Wins 2023 Y-Prize for New Technology that Improves Pulse Oximetry Readings in Patients with Darker Skin
The Equimeter team consisted of undergraduates Ujjayi Pamidigantam (Vagelos LSM), Parthiv Patel (Vagelos LSM), and Advait T. (Vagelos LSM)
Penn Spinouts Nia Therapeutics and Peroxitech Raise Funds for Technological Advancements
Two Penn spinout companies have recently brought in major investments to help further advance their technologies.
Penn Scientists New Research Shows That a CAR-T gel Treatment May Be Able to Kill Residual Cancer Cells Left Over from Surgery
In the study, Penn scientists added CAR-T cells to a gel designed to prevent bleeding after surgery and applied it to the surgical wounds of mice after they had hard-to-treat tumors resected.